decision path change of plans arrows business decision
Biotech

BMS backs out of Dupixent fight, axing asset despite phase 3 win

BMS dropped plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumped the brakes on a would-be Sotyktu successor.
Nick Paul Taylor Feb 7, 2025 6:26am
Parachute over La Jolla California

J&J vet jumps to Affinia—Chutes & Ladders

Feb 7, 2025 8:30am
start line beginning road path starting point journey

Cullinan CEO sets tone for bispecific's upcoming lupus readout

Feb 7, 2025 5:00am
Front view portrait of young female scientist holding petri dish doing experiments with colored liquid

AI-discovered proteins kill bacteria, fungi infecting mice: study

Feb 7, 2025 2:11pm
eGenesis kidney transplant MGH

eGenesis announces 2nd pig kidney transplant success

Feb 7, 2025 2:10pm
Illumina hq

Illumina posts mixed earnings report amid China tariff fallout

Feb 7, 2025 11:25am
Medtech News

BD bids farewell to its diagnostic, bioscience divisions

Feb 6, 2025 1:10pm

LinusBio launches autism diagnostic using single strand of hair

Feb 6, 2025 11:00am

Glucotrack’s 3-year diabetes sensor implant clears human trial

Feb 5, 2025 11:30am

Boston Scientific clocks $1B+ Farapulse revenue in first year

Feb 5, 2025 11:00am